Cargando…
Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines
Live-attenuated measles virus (MeV) has been extraordinarily effective in preventing measles infections and their often deadly sequelae, accompanied by remarkable safety and stability since their first licensing in 1963. The advent of recombinant DNA technologies, combined with systems to generate i...
Autores principales: | Ebenig, Aileen, Lange, Mona V., Mühlebach, Michael D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568972/ https://www.ncbi.nlm.nih.gov/pubmed/36243743 http://dx.doi.org/10.1038/s41541-022-00543-4 |
Ejemplares similares
-
Vaccine platform recombinant measles virus
por: Mühlebach, Michael D.
Publicado: (2017) -
Development of Recombinant Measles Virus-Based Vaccines
por: Mühlebach, Michael D., et al.
Publicado: (2016) -
A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine
por: Hörner, Cindy, et al.
Publicado: (2020) -
Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model
por: Bodmer, Bianca S., et al.
Publicado: (2018) -
Reverse Genetics of Measles Virus and Resulting Multivalent Recombinant Vaccines: Applications of Recombinant Measles Viruses
por: Billeter, M. A., et al.
Publicado: (2009)